Stock Market Prediction Show For Week of January 22 2018

A weekly Saturday night financial show that attempts to predict market direction for the week ahead by looking at a variety of technical and fundamental indicators. Included are the top performing stocks from GuerillaStockTrading that could trend higher over the coming days and weeks driven by strong catalysts or strong fundamentals.
Continue reading “Stock Market Prediction Show For Week of January 22 2018”

Sempra Energy Is One Of The Fastest Growing Utilities

Sempra Energy stock chart shows the biggest positive divergence between large players volume and price so far in 2018. However, the financial health of the company is in question after the Oncor Electric takeover.

Sempra Energy is one of the fastest growing utilities in the industry. Sempra Energy is merging with Oncor Electric which is expected to improve earnings and revenue growth. But there's so much more to like about this stock.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Top 100 Insider Trading Stocks For The Week Ending January 14 2018

Here are the top 100 insider trading stocks for the week. The idea with tracking insider buying is that insiders may have information not widely known by the public. Moves made by insiders can signal information to outsiders. Both insiders and major shareholders that are required to report trades to the SEC are included below.
Continue reading “Top 100 Insider Trading Stocks For The Week Ending January 14 2018”

Ablynx Stock Explodes Higher As Large Players Volume Rises

Ablynx stock is a late-stage clinical development company that is finally going to bring a product to market in Germany in 2018.

Summary

  • 2018 is the year that Ablynx brings Caplacizumab to market in Germany.
  • Novo Nordisk made an unsolicited bid for the company that was rejected.
  • Large players volume and the Twiggs Money Flow are surging higher.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Ampliphi Biosciences Stock 770% Upside From Current Price

    Ampliphi Biosciences stock has rising large players volume after the company released incredible phase 1 trial results from their phage therapy cure for antibiotic resistant superbugs.

    Summary

  • Antibiotic resistant superbugs are on the rise killing more than 23,000 Americans each year.
  • By 2050, 10 million people will die each year from infections that are curable today like ear and paper-cut infections.
  • Phage therapy can kill superbugs but still needs lots of work and FDA approval.
  • Ampliphi Biosciences is conducting several phage therapy clinical trials in 2018.
  • Large players volume is rising in Ampliphi Biosciences stock after incredible clinical trial data was released in early January 2018.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Saturday Stock Market Prediction Show For Week of January 16 2017

    A weekly Saturday night financial show that attempts to predict market direction for the week ahead by looking at a variety of technical and fundamental indicators. Included are the top performing stocks from GuerillaStockTrading that could trend higher over the coming days and weeks driven by strong catalysts or strong fundamentals.
    Continue reading “Saturday Stock Market Prediction Show For Week of January 16 2017”

    Motif Bio’s Antibiotic Resistant Drug and Stock Turnaround

    Motif Bio stock is a high risk, high reward gambit on iclaprim, an antibiotic drug that can kill antibiotic resistant bacteria.

    Summary

  • Motif Bio has developed a bacteria killer using a new approach that could help the drug overcome antibiotic resistance.
  • Iclaprim had solid Phase 3 trial data that demonstrated non-inferiority for all primary endpoints.
  • Large players volume is rising.
  • This is a high, risk high reward gambit.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Winnebago Industries Stock Consolidation Setup

    Winnebago Industries stock finally has consolidated setting up for a compelling long entry. Growth in the towables RV market has exploded higher.

    Summary

  • Winnebago Industries grew revenue by more than 70% last quarter.
  • Winnebago is experiencing high-growth rates in their towables product line.
  • Winnebago stock has finally pulled back and looks like a good long entry.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.